Zosano Pharma (NASDAQ:ZSAN) announced its earnings results on Wednesday. The biotechnology company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01, Fidelity Earnings reports.
ZSAN stock opened at $2.78 on Friday. Zosano Pharma has a 52-week low of $1.85 and a 52-week high of $6.65. The stock’s fifty day simple moving average is $3.07 and its 200-day simple moving average is $3.47. The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $53.52 million, a price-to-earnings ratio of -0.74 and a beta of 2.60.
ZSAN has been the topic of a number of analyst reports. Cantor Fitzgerald initiated coverage on Zosano Pharma in a report on Monday, April 22nd. They set an “overweight” rating and a $3.66 target price on the stock. Zacks Investment Research upgraded Zosano Pharma from a “hold” rating to a “buy” rating and set a $3.50 price objective on the stock in a report on Thursday, June 27th. Finally, ValuEngine upgraded Zosano Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Five investment analysts have rated the stock with a buy rating, Zosano Pharma currently has an average rating of “Buy” and a consensus price target of $8.54.
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Featured Story: Why do corrections happen?
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.